Authors : Ajeet Singh; Nikita Prajapati; Samad Siddiqui; Sajruddin Siddiqui; Manju Panday

Volume/Issue : Volume 11 - 2026, Issue 10 - October

Google Scholar : https://tinyurl.com/bdd5twzc

DOI : https://doi.org/10.38124/ijisrt/26Oct189

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Chronic kidney disease (CKD) is a progressive condition characterized by abnormalities in kidney structure or function that persist over time. The kidneys play an essential role in the elimination of drugs and their metabolites; therefore, impairment of kidney function can significantly affect drug pharmacokinetics and pharmacodynamics. CKD patients are at increased risk of DRPs because of altered renal function, polypharmacy, multiple comorbidities and complicated medication regimens. Common DRPs in CKD include inappropriate drug selection, incorrect dosage, inappropriate dosing frequency, untreated indications, unnecessary drug therapy, drug-drug interactions, adverse drug reactions, medication duplication and non-adherence. Polypharmacy is common among CKD patients because several diseases may need to be treated simultaneously. Although multiple medicines may be clinically necessary, increasing medication burden can increase the possibility of drug-drug interactions, adverse effects, medication errors and poor adherence. Chronic kidney disease (CKD) is a major public health concern due to its high morbidity, mortality, hospitalization rates, healthcare costs, and reduced life expectancy. Globally, Chronic Kidney Disease (CKD) is one of the leading causes of mortality.

Keywords : Chronic Kidney Disease (CKD); Renal Insufficiency; Drug Metabolism; Renal Excretion; Dose Adjustment; Drug Toxicity; Individualized Care; Dialysis; Patient Satisfaction.

References :

1. Zhang S, Zhang GB, Huang P, Ren Y, Lin B, Shao YF, Ye XL. Drug-related problems in hospitalized patients with chronic kidney diseases and clinical pharmacist interventions. BMC Geriatrics.
2. Pehlivanli A, Eyupoglu S, Basgut B, Erturk S, Ozcelikay AT. Impact of a multidisciplinary approach involving clinical pharmacist on resolving drug related problems in chronic kidney patients: a prospective interventional study. BMC Nephrol. 2023;24:149. doi:10.1186/s12882-023-03210-5.
3. Bezie GA, Adugna M, Wassie GT. Renal drug dosing practices and clinical outcomes in patients with kidney disease admitted at two referral hospitals in Northwest Ethiopia. BMC Nephrology.2025;26:474.doi:10.1186/s12882-025-04410-x.
4. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117. doi:10.1186/1471-2458-8-117.
5. Roy DA, Shanfar I, Shenoy P, Chand S, Nandakumar UP, Raj KC B. Drug-related problems among chronic kidney disease patients: a clinical pharmacist led study. Int J Pharm Res. 2020;12(4):79-84. doi:10.31838/ijpr/2020.12.04.017.
6. Collister D, Russell R, Verdon J, Beaulieu M, Levin A. Perspectives on optimizing care of patients in multidisciplinary chronic kidney disease clinics. Can J Kidney Health Dis. 2016;3:32. doi:10.1186/s40697-016-0122-9.
7. Olyaei AJ, Steffl JL. A Quantitative Approach to Drug Dosing in Chronic KidneyDisease.BloodPurification.2011;31:138–145. doi:10.1159/000321857
8. Hassan Y, Al-Ramahi RJ, Abd Aziz N, Ghazali R. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Annals of Pharmacotherapy.2009;43:1598–1605.doi:10.1345/aph.1M187.
9. Ikizler TA, Cuppari L. The 2020 updated KDOQI clinical practice guidelines for nutrition in chronic kidney disease. BloodPurif.2021;50:667671.doi:10.1159/000513698.
10. Patwardhan MB, Samsa GP, Matchar DB, Haley WE. Advanced chronic kidney disease practice patternamong nephrologists and non-nephrologists: a database analysis. Clin J Am Soc Nephrol. 2007;2:277–283
11. Shahbaz H, Rout P, Gupta M. Creatinine Clearance. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Updated 2024 Jul 27
12. Bugnicourt JM, Godefroy O, Chillon JM, Choukroun G, Massy ZA. Cognitive disorders and dementia in CKD: The neglected kidney-brain axis. J Am Soc Nephrol. 2013;24(3):353–63.
13. Novak M, Mucsi I, Mendelssohn DC.     Screening for depression: Only one   piece of the puzzle. Nephrol Dial Transplant. 2013;28(6):1336–40.
14. Tiffin-Richards FE, Costa AS, Holschbach B, et al. The Montreal Cognitive
15. Nagasawa H, Tachi T, Sugita I, Esaki H, Yoshida A, Kanematsu Y, et al. The effect of quality of life on medication compliance among dialysis patients. Front Pharmacol. 2018;9:488. doi:10.3389/fphar.2018.
16. Alruqayb WS, Price MJ, Paudyal V, Cox AR. Drug-related problems in hospitalised patients with chronic kidney disease: a systematic review. Drug Safety. 2021;44(10):1041–1058. doi:10.1007/s40264-021-01099-3.
17. Saguban R, Shanmugam SR, Rondilla E, Buta J, Alatawi NAH, Maestrado R, et al. Self-Efficacy, Social Support, and Depression: Mediators of Medication Adherence in Dialysis Patients. Healthcare.2025;13:425.doi:10.3390/healthcare13040425.
18. Owsiany MT, Hawley CE, Paik JM. Differential diagnoses and clinical implications of medication nonadherence in older patients with chronic kidney disease: a review. Drugs Aging. 2020;37(12):875–884. doi:10.1007/s40266-020-00804-8.
19. Owsiany MT, Hawley CE, Paik JM. Differential Diagnoses and Clinical Implications of Medication Nonadherence in Older Patients with Chronic Kidney Disease: A Review. Drugs Aging. 2020;37(12):875-884. doi:10.1007/s40266-020-00804-8.
20. Rifkin DE, Laws MB, Rao M, Balakrishnan VS, Sarnak MJ, Wilson IB. Medication adherence behavior and priorities among older adults with CKD: a semi-structured interview study. Am J Kidney Dis. 2010;56(3):439 doi:11053/j.ajkd.2010.04.021. [PubMed: 20674113]
21. Steinman MA, Miao Y, Boscardin WJ, Komaiko KD, Schwartz JB. Prescribing quality in older veterans: a multifocal approach. J Gen Intern Med. 2014;29(10):1379–86.doi:10.1007/s11606-014-2924-8. [PubMed: 25002159]
22. Ada S, Ozcan SG. Comparison of mood status and treatment adherence between dialysis     modalities. Ther Apher Dial. 2025;29(4):639–45. https://doi.rg/10.1111/1744-9987.70018. Epub 2025 Apr 13. PMID: 40223269.
23. Afshari M, Karimi-Shahanjarini A, Tapak L, Hashemi S. Determinants of medication adherence among elderly with high blood pressure living in deprived areas. Chronic Illn. 2024;20(3):487–503. https://doi.org/10.1177/17423953241241803. Epub 2024 Jun 12. PMID: 38866539.
24. Amado L, Ferreira N, Miranda V, Meireles P, Povera V, Ferreira R, et al. Selfreported medication adherence in patients with end-stage kidney disease undergoing online-haemodiafiltration. J Ren Care. 2015;41(4):231–38.https://doi.org/10.1111/jorc.12127. Epub 2015 May 4
25. Amado L, Ferreira N, Miranda V, Meireles P, Povera V, Ferreira R, et al. Self-reported medication adherence in patients with end-stage kidney disease undergoing online-haemodiafiltration. J Ren Care. 2015;41(4):231–38. https://doi.org/10.1111/jorc.12127. Epub 2015 May 4.
26. Bandiera C, Dotta-Celio J, Locatelli I, Nobre D, Wuerzner G, Pruijm M, et al. The  differential impact of a 6-versus 12-month pharmacist-led interprofessional medication adherence program on medication adherence in patients with diabetic kidney disease: the randomized PANDIA-IRIS study. Front Pharmacol. 2024;15:1294436. https://doi.org/10.3389/fphar.2024.1294436. PMID: 38327981; PMCID: PMC10847300.
27. Bandiera C, Pasquier J, Locatelli I, Niquille A, Wuerzner G, Dotta-Celio J, et al. Medication adherence evaluated through electronic monitors during the 2020 COVID-19 pandemic lockdown in Switzerland: a longitudinal analysis. Patient Prefer Adherence. 2022;16:2313–20. https://doi.org/10.2147/PPA.S377780.
28. Janse RJ, Fu EL, Dahlström U, Benson L, Lindholm B, van Diepen M, et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician’s prescriptions to patient’s dispensations, medication adherence and persistence. Eur J Heart Fail.2022;24(11):2185–95. https://doi.org/10.1002/ejhf.2620. Epub 2022 Aug 2.
29. Kanakubo Y, Inanaga R, Toida T, Aita T, Ukai M, Kawaji A, et al. Trust in physi-cians as a mediator of the relationship between person-centered care and medication adherence in patients undergoing hemodialysis: a cross-sectional study. J Nephrol. 2025. https://doi.org/10.1007/s40620-025-02387-2. Epub ahead of print. Erratum in: J Nephrol. 2025 Oct 29. https://doi.org/10.1007/s40620-025-02457-5. PMID: 40828491.
30. Kaul S, Ahsan A, Singh NP, Khullar D, Gupta AK. Evaluation of medication adherence in chronic kidney disease patients with and without Hemodialysis. Indian J Med Spec. 2023;14(3):162–67. https://doi.org/10.4103/injms.injms_6_23.
31. Khokhar A, Khan YH, Mallhi TH, et al. Effectiveness of pharmacist intervention model for chronic kidney disease patients; a prospective comparative study. Int J Clin Pharm. 2020;42:625–34. https://doi.org/10.1007/s11096-020-00982-w.
32. Kronish IM, Moise N, McGinn T, Quan Y, Chaplin W, Gallagher BD, et al. An electronic adherence measurement intervention to reduce clinical inertia in the treatment of uncontrolled hypertension: the MATCH Cluster randomized clinical trial. J Gen Intern Med. 2016;31(11):1294–300. https://doi.org/10.1007/s11606-016-3757-4. Epub 2016 Jun 2.
33. Lassen MCH, Johansen ND, Modin D, Catarig AM, Vistisen BK, Amadid H, et al. Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: a nationwide registry study. Diabetes Obes Metab. 2024;26(11):5239–50. https://doi.org/10.1111/dom.15872. Epub 2024 Aug 31. PMID: 39215626
34. Hsu KL, Fink JC, Ginsberg JS, Yoffe M, Zhan M, Fink W, Woods CM, Diamantidis CJ. Self-reported Medication Adherence and Adverse Patient Safety Events in CKD. Am J Kidney Dis. 2015;66(4):621–629. doi:10.1053/j.ajkd.2015.03.026.